Dr. Julie Dumonceaux, Professor at University College London Great Ormond Street Institute of Child Health in London, England, discusses her lab's FSHD work and overall FSHD efforts in the UK with MyFSHD UK Ambassador Kate Fowles.

Dr. Charis Himeda joins us again to talk all types of FSHD therapeutic approaches

A primer on epigenetic gene and genome regulation and how it relates to FSHD

Dr. Alexandra Belayew from the University of Mons in Belgium and the discoverer of DUX4 sits down with volunteer MyFSHD Ambassador Jenny Hasenjaeger to discuss the discovery of DUX4, the Fulcrum Losmapimod trial, antisense, and a little bit of everything FSHD.

A short primer on the genetic differences and similarities between FSHD1, FSHD2, and FSHD1+2 just to make sure we are all up to speed.

Dr. Peter Jones sits down with Dr. Charis Himeda to discuss her invention of CRISPR-inhibition for FSHD, some of the bumps along the way, and its ultimate therapeutic potential and constraints.  In addition, other CRISPR technology that is being developed for FSHD is discussed.

Dr Peter Jones explains genetic diagnostics for FSHD1 and FSHD2.  This covers various methods for FSHD deletion testing through the new epigenetic research testing, and the difference between CLIA-approved testing and research testing.  The final 20 minutes takes you through your FSHD genetic report if you participated in the epigenetic research testing at the Jones Lab at UNR.

Dr. Peter Jones sits down with Dr. Ryan Wuebbles to discuss his journey with FSHD first as a patient and now as a researcher.  Covers some FSHD basics, research approaches, and how you can be the best advocate for FSHD.